Antileukotriene drugs in the treatment of bronchial asthma;Gli antileucotrienici nella terapia dell'asma bronchiale

Recenti Progressi in Medicina

Volumn 94, Issue 11, 2003, Pages 509-515

  Riccioni, Graziano ^a,c   Della Vecchia, Rosanna ^b   Menna, Vincenzo ^a   Savino Lambo, Massimo ^a   Di Ilio, Carmine ^a   D'Orazio, Nicolantonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale SS Annunziata   (Italy)

^c NONE   (Italy)

Author keywords

Bronchial asthma; Bronchial hyperresponsiveness; Inhaled corticosteroids; Leukotriene; Leukotriene receptor antagonists; Management

Indexed keywords

CORTICOSTEROID; PEPTIDOLEUKOTRIENE;

AIRWAY; ASTHMA; BIOAVAILABILITY; BRONCHOSPASM; DISEASE SEVERITY; EXERCISE; HEALTH CARE; HUMAN; INFLAMMATORY CELL; MEDICAL EDUCATION; MONOTHERAPY; NOSE CONGESTION; PATHOPHYSIOLOGY; REVIEW; RHINITIS;

EID: 0344010026     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. National Asthma Education and Prevention Program 1997. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. NIH Publication no. 97-4051. Bethesda: National Institutes of Health.
2. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S3.
3. Kelloway CH, Trethewie ER. The liberation of a slow-reacting smooth-muscle stimulating substance in anaphylaxis. Quart J Exp Physiol 1940; 30: 121-45.
4. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620-4.
5. Wardlaw AJ, Hay H, Cromwell O, Collins JW, Kay AB. Leukotyrienes, LTC4 and LTB4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19-26.
6. Wenzel E, Larsen GL, Johnston H, Voelkel BF, Wescott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatic after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112-9.
7. Dahlen SE. Leukotrienes as mediators of airway obstruction and bronchial provocation hyperresponsiveness. In: Page C, Gardiner PJ, eds. Airway hyperresponsiveness: is it really important for asthma? Oxford: Blackwell Scientific Publications 1993; 188-205.
8. Chung KF, Barnes PJ. Cytochines in asthma. Thorax 1999; 54: 825.
9. Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CM, et al. A humanized anti-IL-5 monoclonal antibody; initial single dose safety and activity in patients with asthma. Am J Respir Crit Care Med 1999; 159: 45-47.
10. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-75.
11. Bell EH, Timmers MC, Hermans J, Dijkman H, Sterk PJ. The long-term effect of nedocromile sodium and beclometasone dipropionate on bronchial responsiveness methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990; 141: 21-24.
12. Barnes PJ. Effect of corticosteroid on airway hyperresponsiveness. Am Rev Respir Dis 1990; 141: S70-S76.
13. Booth H, Richmond I, Ward J, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152: 45-52.
14. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-43.
15. Chanez P, Paradis L, Vignola AM. Changes in bronchial inflammation of steroids (GCs) dependent asthmatics. Am J Respir Crit Care Med 1996; 153: A212.
16. Pizzichini MM, Pizzichini E, Clelland L, Efthimiadis A, Pavord I, Dolovich J, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999; 13: 15-21.
17. Poiani GJ, Tozzi CA, Thakker-Varia S, Choe JK, Riley DJ. Effect of glucocorticoids on collagen accumulation in pulmonary vascular remodeling in the rat. Am J Respir Crit Care Med 1994; 149: 994-9.
18. Northup JK, Valentine-Braun KA, Johnston LK, Severson DL, Hollenmerg MD. Evaluation of the anti-inflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I. J Clin Invest 1988; 82: 1347-52.
19. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
20. Smith LJ, Hanby LA, Lavins BJ, Simonson SG1. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 1998; 81: 43-9.
21. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5- lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-4.
22. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789-93.
23. Pynaert G, Grooten J, van Deventer SJ, Peppelenbosch MP. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. Mol Med 1999; 5: 685-92.
24. Dekhuijzen PN, Bootsma GP, Wielders PL, Wielders PL, van den Berg LR, Festen J, et al. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. Eur Respir J 1997; 10: 2749-53.
25. Allegra L, Fasano V, Raiteri L, Morelli N, Carratu P, Guerra S, et al. Zafirlukast single oral dose pre-treatment prevents FEV1 drop after bronchial challenge in mild asthma [abstract]. Eur Respir J 1999; 14 (suppl 30): 122S.
26. Macfarlane A, Manning P, Ryan M, Naya I, Harris A, Pavord ID, et al. Zafirlukast and low dose baclomethasone protect against early (EAR) and late asthmatic responses (LAR) and allergen induced eosinophilia in mild atopic asthma [abstract]. Eur Respir J 1999; 14 (suppl 30): 121S.
27. Diamant Z, Grootendorst DC, Veselic-Charvat M, Tim-mers MC, De Smet M, Leff JA, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29: 42-51.
28. Riccioni G, Castronuovo M, De Benedictis M, Pace-Palitti V, Di Gioacchino M, Della Vecchia R, et al. Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopath Pharmacol 2001; 14: 87-92.
29. Riccioni G, Ballone E, Sensi S, Di Nicola M, Di Mascio R, Santilli F, et al. Effectiveness of monteukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopath Pharmacol 2002; 15: 149-55.
30. Tohda Y, Nakahara H, Kubo H. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999; 29: 1532-6.
31. Riccioni G, D'Orazio N, Di Ilio, Della Vecchia R, De Lorenzo A. Effectiveness and safety of montelukast versus budesonide at different doses on bronchial reactivity in subjects with mild-persistent asthma. Clin Terap 2002; 153: 317-21.
32. Coward SM, Hill AA, Kilfeather SA. Leukotriene synthesis inhibition can interrupt antigen-induced sensitisation [abstract]. Eur Respir J 1999; 14 (suppl 30): 156S.
33. Hisada T, Salmon M, Nasuhara Y, et al. Cysteinyl leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. Am J Respir Crit Care Med 1999; 160: 571-5.
34. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial; Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213-20.
35. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study; The Zafirlukast Trialist Group. Clin Ther 1997; 19: 675-90.
36. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma; Montelukast Asthma Study Group. Eur Respir J 1998; 11: 1232-9.
37. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicenter clinical study in asthma. Thorax 1997; 52: 523-7.
38. Virchow JC, Hassall SM, Summerton L, Harris A. Improved asthma control > 6 weeks with Zafirlukast in patients on high dose inhaled corticosteroids [abstract]. Eur Respir J 1997; 10 (S25): 437S.
39. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155: 1235-40.
40. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
41. Stevenson DD, Simon RA. Sensitivity to aspirin and non-steroidal anti-inflammatory drugs. St Louis: Mosby 1993; 1747-65.
42. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM Sala A, Vaghi A, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153: 572-5.
43. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklika A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-46.
44. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Rriss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: randomized, double-blind trial; Pediatric Montelukast Study Group. JAMA 1998; 279: 1181-6.
45. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegal SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66.
46. Anderson SD. Is there a unifying hypothesis for exercise-induced asthma? J Allergy Clin Immunol 1984; 73: 660-5.
47. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka QK, Bronsky E. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030-5.
48. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kempb J, Hendeles L, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-52.
49. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF De Luca PT, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise bronchoconstriction: a randomized double-blind trial. Ann Intern Med 2000; 132: 97-104.
50. Capristo AF, del Giudice MM, Maiello M. Montelukast for treatment of exercise-induced asthma in children: mid-term study [abstract]. Eur Respir J 1999; 14 (suppl 30): 42S.
51. Riccioni G, Ballone E, D'Orazio N, Sensi S, Di Nicola M, Di Mascio R, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopathol Pharmacol 2002; 15: 149-55.
52. Riccioni G, Della Vecchia R, D'Orazio N, Sensi S, Guagnano MT. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm Pharmacol Ther 2003; 16: 111-4.
53. Global Initiative for Asthma: Global strategy for asthma management and prevention. Bethesda: National Heart, Lung and Blood Institute, National Institute of Health; revised 2002. Updated from: NHLBI/WHO Workshop Report: Global strategy for asthma management and prevention, issued January 1995. NIH Publication n° 02-3659.